| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 26.11 | 2231 |
| Intrinsic value (DCF) | 0.39 | -65 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Hyperfine, Inc. (NASDAQ: HYPR) is an innovative medical technology company specializing in portable magnetic resonance imaging (MRI) solutions. Founded in 2014 and headquartered in Guilford, Connecticut, Hyperfine is revolutionizing point-of-care diagnostics with its flagship Swoop Portable MR Imaging System. This FDA-cleared, low-field MRI device is designed to provide accessible, cost-effective imaging at the patient's bedside, addressing critical gaps in neurological and critical care settings. Operating in the $7B+ global MRI market, Hyperfine targets hospitals, emergency departments, and underserved regions where traditional high-field MRI systems are impractical. The company combines proprietary AI-powered software with portable hardware to deliver real-time imaging, reducing diagnostic delays. With a focus on democratizing medical imaging, Hyperfine aligns with healthcare trends toward decentralized care and value-based solutions. Its asset-light model emphasizes recurring revenue through software subscriptions and services.
Hyperfine presents a high-risk, high-reward proposition for growth-oriented investors. The company's disruptive Swoop system addresses a clear unmet need in portable neuroimaging, with a total addressable market exceeding $3B in the U.S. alone. However, with a market cap of just $42M and negative operating cash flows (-$38.8M), commercialization execution remains critical. Key risks include slow adoption of low-field MRI by clinicians accustomed to high-field systems, reimbursement challenges, and competition from emerging portable imaging technologies. The company's $37.6M cash position provides ~12 months of runway at current burn rates, suggesting potential dilution risk. Investors should monitor order traction, clinical validation studies, and partnerships with healthcare systems. The 1.04 beta indicates market-correlated volatility.
Hyperfine's competitive edge stems from being first-to-market with an FDA-cleared portable MRI system, protected by 75+ patents. The Swoop's unique value proposition includes 10x lower cost ($50K vs. $1M+ for traditional MRI), zero radiation, and bedside operation—advantages particularly compelling for pediatric, ICU, and rural applications. However, the company faces significant challenges in displacing incumbent MRI manufacturers who benefit from clinician familiarity and superior image resolution. Hyperfine's 0.064T low-field technology trades off some diagnostic capability for portability, limiting its use to specific indications like hydrocephalus monitoring. The company mitigates this through AI-enhanced image reconstruction (DeepResolve software) and a razor-and-blades model combining device sales with SaaS revenue. Competitive threats loom from Chinese portable MRI developers and potential moves by GE HealthCare or Siemens into the low-field segment. Hyperfine's niche focus on point-of-care neurology provides differentiation but requires substantial clinician education to drive adoption beyond early adopter institutions.